Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ola Weiland

Showing results (1-10 of 95) with videos related to

Pageof 10
Sort By:
Lakartidningen|November 26, 2014
[Breakthrough in the treatment of chronic hepatitis C virus infections. Direct acting antivirals heals over 90 percent]Ola Weiland
Journal of Hepatology|May 19, 2009
What offers the best prediction of sustained virologic response during combination therapy with interferon and ribavirin: viral dynamics, viral levels at certain time points, or a combination of both?Ola Weiland
Lakartidningen|June 26, 2008
[Immunoglobulin or vaccine as post-exposure prophylaxis against hepatitis A. The vaccine is sufficient for many according to the first controlled study]Ola Weiland
Scandinavian Journal of Infectious Diseases|July 16, 2014
In memoriam--Professor Ragnar Norrby (1943-2014)Arne Tärnvik, Ola Weiland
Scandinavian Journal of Infectious Diseases|March 11, 2010
Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patientsJenny Nilsson, Ola Weiland
Lakartidningen|February 26, 2010
[Measurement of liver elasticity can differentiate high and low grade fibrosis. New method can reduce the need of liver biopsy in chronic hepatitis C]Ann Wejdmark, Ola Weiland
Liver International : Official Journal of the International Association for the Study of the Liver|February 21, 2020
Hepatitis C elimination - Macro-eliminationMartin Kåberg, Ola Weiland
Scandinavian Journal of Infectious Diseases|November 18, 2014
Editorial--an introduction to the new Infectious DiseasesArne Tärnvik, Ola Weiland
Scandinavian Journal of Infectious Diseases|September 14, 2007
High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantationErika Hörnfeldt, Henrik Gjertsen, Ola Weiland
Journal of Medical Virology|March 25, 2008
Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methodsTony Carlsson, Anne Quist, Ola Weiland
Pageof 10

Showing results (1-10 of 95) with videos related to

Sort By:
Pageof 10
Lakartidningen|November 26, 2014
[Breakthrough in the treatment of chronic hepatitis C virus infections. Direct acting antivirals heals over 90 percent]Ola Weiland
Journal of Hepatology|May 19, 2009
What offers the best prediction of sustained virologic response during combination therapy with interferon and ribavirin: viral dynamics, viral levels at certain time points, or a combination of both?Ola Weiland
Lakartidningen|June 26, 2008
[Immunoglobulin or vaccine as post-exposure prophylaxis against hepatitis A. The vaccine is sufficient for many according to the first controlled study]Ola Weiland
Scandinavian Journal of Infectious Diseases|July 16, 2014
In memoriam--Professor Ragnar Norrby (1943-2014)Arne Tärnvik, Ola Weiland
Scandinavian Journal of Infectious Diseases|March 11, 2010
Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patientsJenny Nilsson, Ola Weiland
Lakartidningen|February 26, 2010
[Measurement of liver elasticity can differentiate high and low grade fibrosis. New method can reduce the need of liver biopsy in chronic hepatitis C]Ann Wejdmark, Ola Weiland
Liver International : Official Journal of the International Association for the Study of the Liver|February 21, 2020
Hepatitis C elimination - Macro-eliminationMartin Kåberg, Ola Weiland
Scandinavian Journal of Infectious Diseases|November 18, 2014
Editorial--an introduction to the new Infectious DiseasesArne Tärnvik, Ola Weiland
Scandinavian Journal of Infectious Diseases|September 14, 2007
High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantationErika Hörnfeldt, Henrik Gjertsen, Ola Weiland
Journal of Medical Virology|March 25, 2008
Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methodsTony Carlsson, Anne Quist, Ola Weiland
Pageof 10